Back to Search Start Over

Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.

Authors :
Ziemann M
Altermann W
Angert K
Arns W
Bachmann A
Bakchoul T
Banas B
von Borstel A
Budde K
Ditt V
Einecke G
Eisenberger U
Feldkamp T
Görg S
Guthoff M
Habicht A
Hallensleben M
Heinemann FM
Hessler N
Hugo C
Kaufmann M
Kauke T
Koch M
König IR
Kurschat C
Lehmann C
Marget M
Mühlfeld A
Nitschke M
Pego da Silva L
Quick C
Rahmel A
Rath T
Reinke P
Renders L
Sommer F
Spriewald B
Staeck O
Stippel D
Süsal C
Thiele B
Zecher D
Lachmann N
Source :
Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2019 Jul 05; Vol. 14 (7), pp. 1056-1066. Date of Electronic Publication: 2019 Jun 18.
Publication Year :
2019

Abstract

Background and Objectives: The prognostic value of preformed donor-specific HLA antibodies (DSA), which are only detectable by sensitive methods, remains controversial for kidney transplantation.<br />Design, Setting, Participants, & Measurements: The outcome of 4233 consecutive kidney transplants performed between 2012 and 2015 in 18 German transplant centers was evaluated. Most centers used a stepwise pretransplant antibody screening with bead array tests and differentiation of positive samples by single antigen assays. Using these screening results, DSA against HLA-A, -B, -C, -DRB1 and -DQB1 were determined. Data on clinical outcome and possible covariates were collected retrospectively.<br />Results: Pretransplant DSA were associated with lower overall graft survival, with a hazard ratio of 2.53 for living donation (95% confidence interval [95% CI], 1.49 to 4.29; P< 0.001) and 1.59 for deceased donation (95% CI, 1.21 to 2.11; P =0.001). ABO-incompatible transplantation was associated with worse graft survival (hazard ratio, 2.09; 95% CI, 1.33 to 3.27; P =0.001) independent from DSA. There was no difference between DSA against class 1, class 2, or both. Stratification into DSA <3000 medium fluorescence intensity (MFI) and DSA ≥3000 MFI resulted in overlapping survival curves. Therefore, separate analyses were performed for 3-month and long-term graft survival. Although DSA <3000 MFI tended to be associated with both lower 3-month and long-term transplant survival in deceased donation, DSA ≥3000 MFI were only associated with worse long-term transplant survival in deceased donation. In living donation, only strong DSA were associated with reduced graft survival in the first 3 months, but both weak and strong DSA were associated with reduced long-term graft survival. A higher incidence of antibody-mediated rejection within 6 months was only associated with DSA ≥3000 MFI.<br />Conclusions: Preformed DSA were associated with an increased risk for graft loss in kidney transplantation, which was greater in living than in deceased donation. Even weak DSA <3000 MFI were associated with worse graft survival. This association was stronger in living than deceased donation.<br /> (Copyright © 2019 by the American Society of Nephrology.)

Details

Language :
English
ISSN :
1555-905X
Volume :
14
Issue :
7
Database :
MEDLINE
Journal :
Clinical journal of the American Society of Nephrology : CJASN
Publication Type :
Academic Journal
Accession number :
31213508
Full Text :
https://doi.org/10.2215/CJN.13401118